- Home
- RVT vs AGIO Comparison
RVT vs AGIO Comparison
Compare RVT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVT
- AGIO
- Stock Information
- Founded
- RVT 1986
- AGIO 2007
- Country
- RVT United States
- AGIO United States
- Employees
- RVT N/A
- AGIO N/A
- Industry
- RVT Trusts Except Educational Religious and Charitable
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- RVT Finance
- AGIO Health Care
- Exchange
- RVT Nasdaq
- AGIO Nasdaq
- Market Cap
- RVT 1.9B
- AGIO 2.0B
- IPO Year
- RVT N/A
- AGIO 2013
- Fundamental
- Price
- RVT $14.51
- AGIO $28.44
- Analyst Decision
- RVT
- AGIO Buy
- Analyst Count
- RVT 0
- AGIO 8
- Target Price
- RVT N/A
- AGIO $56.57
- AVG Volume (30 Days)
- RVT 243.4K
- AGIO 634.7K
- Earning Date
- RVT 01-01-0001
- AGIO 05-01-2025
- Dividend Yield
- RVT 7.32%
- AGIO N/A
- EPS Growth
- RVT N/A
- AGIO N/A
- EPS
- RVT 2.95
- AGIO 11.64
- Revenue
- RVT N/A
- AGIO $36,498,000.00
- Revenue This Year
- RVT N/A
- AGIO $50.61
- Revenue Next Year
- RVT N/A
- AGIO $223.79
- P/E Ratio
- RVT $4.98
- AGIO $2.44
- Revenue Growth
- RVT N/A
- AGIO 36.07
- 52 Week Low
- RVT $11.85
- AGIO $26.66
- 52 Week High
- RVT $14.93
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- RVT 43.70
- AGIO 36.15
- Support Level
- RVT $14.03
- AGIO $26.66
- Resistance Level
- RVT $14.65
- AGIO $32.90
- Average True Range (ATR)
- RVT 0.25
- AGIO 1.36
- MACD
- RVT 0.05
- AGIO -0.30
- Stochastic Oscillator
- RVT 58.54
- AGIO 28.53
About RVT Royce Value Trust Inc.
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.